Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma.

Aline TalhoukHeather DerocherPascal SchmidtSamuel LeungKaty MilneC Blake GilksMichael S AnglesioBrad H NelsonJessica N McAlpine

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)

Immune response correlates with endometrial cancer molecular subtype but does not carry independent prognostic significance. Profound variation in immune response is seen across and within endometrial cancer molecular subtypes, suggesting that assessment of immune response rather than molecular subtype may better predict response to immunotherapy.See related commentary by Mullen and Mutch, p. 2366.

Keyphrases

endometrial cancer
immune response
dendritic cells
toll like receptor
metabolic syndrome
type diabetes
inflammatory response